Unicycive Therapeutics UNCY 深 沪
等待开盘 10-09 09:30:00 美东时间
4.07
-0.110
-2.63%
华盛通- 最 高4.1994
- 今 开4.16
- 成交量 117.61万股
- 最 低 4.0301
- 昨 收 4.18
- 总市值 1.13亿
- 52周最高 8.74
- 市盈率 静 --
- 换手率 4.22%
- 52周最低 3.93
- 委 比 99.48%
- 总股本 2785.53万
- 历史最高 87.30
- 量 比 1.27
- 振 幅 4.05%
- 历史最低 2.02
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain Officers
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001766140/000121390026104076/ea0306890-8k_unicycive.htm
09-29 04:37
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.
08-20 23:38
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
08-13 21:56
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.34) by 82.35 percent. This is a 88.46 percent increase over losses of $(0.52) per share from the same period last year.
08-12 18:43
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics reported financial results for Q2 2026, with $61.4M in cash, and provided updates on oxylanthanum carbonate (OLC) NDA progress. The company awaits FDA inspection of its third-party manufacturing vendor, with plans to resubmit the NDA upon successful completion. OLC's commercial launch preparations are ongoing, including market awareness campaigns. R&D expenses increased by $1M, while G&A expenses rose by $2.2M, driven by st...
08-12 11:19
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Prediction market platform Kalshi is expanding into biotech, launching contracts Wednesday night that let traders bet on clinical trial outcomes and drug approvals from companies including Sanofi (NASDAQ:SNY) and Gilead Sciences Inc (NASDAQ:GILD). The 13 new contracts were launched in partnership wi...
07-17 01:29
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
